Raiffeisen Bank International AG Invests $41.13 Million in Zoetis Inc. (NYSE:ZTS)

Raiffeisen Bank International AG acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 253,498 shares of the company’s stock, valued at approximately $41,128,000. Raiffeisen Bank International AG owned approximately 0.06% of Zoetis as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ZTS. Vanguard Group Inc. increased its holdings in Zoetis by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock valued at $6,739,905,000 after buying an additional 120,158 shares during the last quarter. Geode Capital Management LLC grew its holdings in Zoetis by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock valued at $1,726,075,000 after purchasing an additional 190,137 shares during the last quarter. Polen Capital Management LLC boosted its stake in shares of Zoetis by 17.5% during the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock worth $1,219,237,000 after purchasing an additional 1,116,541 shares during the last quarter. Wellington Management Group LLP lifted its position in Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after buying an additional 3,059,255 shares during the period. Finally, Northern Trust Corp boosted its holdings in Zoetis by 13.3% in the fourth quarter. Northern Trust Corp now owns 6,426,394 shares of the company’s stock valued at $1,047,052,000 after acquiring an additional 755,893 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several recent analyst reports. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Stifel Nicolaus reduced their price objective on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. Piper Sandler upped their target price on Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a research report on Monday. UBS Group lowered their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Finally, Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $212.75.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Zoetis Trading Down 3.5%

Shares of NYSE ZTS opened at $154.77 on Thursday. The firm has a 50 day moving average price of $156.72 and a two-hundred day moving average price of $165.71. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The stock has a market cap of $68.90 billion, a P/E ratio of 28.29, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.